TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A meta-analysis of seven placebo-controlled trials found that neurokinin-receptor antagonists were associated with improved patient-reported sleep disturbance among menopausal women with moderate-to-severe hot flashes. Benefits were observed by four weeks and continued through 24 weeks, but the findings do not show whether sleep improved independently of hot-flash relief.
A meta-analysis of seven placebo-controlled trials found that nonhormonal neurokinin-receptor drugs were associated with reduced sleep disturbance in menopausal women with moderate-to-severe hot flashes, with improvement reported as early as four weeks. The findings, presented at the Menopause Society annual meeting and published in Menopause, add evidence about sleep outcomes for women seeking alternatives to hormone therapy.
The review included data from 3,184 women: 949 received fezolinetant, 864 received elinzanetant, and 1,371 received placebo. The researchers searched PubMed, Embase and Cochrane through May 2026. All seven included trials were assessed as having a low risk of bias, according to the report.
Five trials used the same validated PROMIS Sleep Disturbance-Short Form 8b questionnaire, which asks about sleep quality, restfulness, and difficulty falling or staying asleep during the previous seven days. On this scale, lower scores mean less sleep disturbance. Compared with placebo, the pooled analysis found an improvement at four weeks (standardized mean difference, or SMD, -3.94; 95% confidence interval -5.71 to -2.16), at 12 weeks (SMD -3.11; 95% CI -4.60 to -1.61), and at 24 weeks (SMD -2.04; 95% CI -3.93 to -0.15).
In subgroup analyses, both drugs significantly improved sleep scores through 12 weeks. The estimated effect was larger for elinzanetant than fezolinetant at four weeks and 12 weeks, but the researchers said head-to-head trials are needed to compare the medicines directly. The other two trials used different sleep questionnaires and were analyzed separately.
Sleep Relief Beyond Hot Flashes
Sleep disruption can be a major complaint for people experiencing menopausal hot flashes, and treatment choices may be limited for those who cannot use hormone therapy or prefer not to. The results provide pooled evidence that two nonhormonal options may improve reported sleep disturbance while treating vasomotor symptoms.
The findings do not establish that either drug should be chosen specifically as a sleep treatment, nor do they show that sleep benefits occur separately from fewer or less severe hot flashes. Still, the reported improvement by four weeks may help patients and clinicians discuss what outcomes to monitor when considering treatment. Individual treatment decisions should be made with a qualified health professional.
neurokinin receptor antagonists for menopause sleep
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Drugs Target Hot Flashes
Menopausal hormone therapy is a preferred treatment for vasomotor symptoms, but it is not suitable or wanted by every patient. Fezolinetant (Veozah) blocks the NK3 receptor, while elinzanetant (Lynkuet) blocks NK1 and NK3 receptors. These medicines act on pathways involved in the brain’s regulation of body temperature, which may reduce hot flashes and related symptoms.
The research team, led by Maria Julia Lemos, MD, of Kurah Women’s Health Institute in Macaé, Brazil, undertook the review because large trials had measured sleep as a secondary outcome, but a meta-analysis focused on sleep had not yet been conducted, according to Lemos’s comments to MedPage Today. The review combined results from trials including OASIS I, II and III, SWITCH-1, DAYLIGHT, SKYLIGHT I and II, and a 2019 study by Depypere and colleagues.
“For women with hot flashes who can’t or don’t want to use hormone therapy, especially when poor sleep is one of their main complaints, these drugs are a good option to consider.”
— Maria Julia Lemos, MD, lead researcher, speaking to MedPage Today
Limits of the Sleep Evidence
The analysis included only seven trials, and participants, drug regimens and follow-up periods varied. Sleep outcomes were based on patient reports rather than an objective measure, and the review authors noted substantial heterogeneity across the studies. The pooled estimates also came from trials using a shared questionnaire; two studies with different instruments could not be combined in the same way.
It remains unclear how much of the reported sleep improvement came from reduced hot flashes and how much, if any, reflected an effect on sleep independent of vasomotor symptom relief. The larger estimated effect for elinzanetant in subgroup analyses does not establish that it works better than fezolinetant for an individual patient. Direct comparison trials are still needed.
Direct Comparisons Still Needed
The next evidence milestone identified by Lemos is a head-to-head trial comparing fezolinetant and elinzanetant. Such research could clarify differences in sleep outcomes, but the supplied report does not specify whether or when a direct comparison is planned.
For now, the meta-analysis adds sleep-related findings to evidence on drugs used for menopausal vasomotor symptoms. Clinicians and patients will need to weigh the results alongside each person’s symptoms, medical history, treatment preferences and the limitations of the available studies. The report does not establish a separate indication for treating insomnia with these medicines.
Key Questions
Which medicines were included in the analysis?
The review examined fezolinetant and elinzanetant, nonhormonal neurokinin-receptor drugs studied for menopausal vasomotor symptoms.
How soon did the studies report a sleep benefit?
The pooled results showed improved patient-reported sleep-disturbance scores by four weeks, with improvements also reported at 12 and 24 weeks compared with placebo.
Does the analysis prove the drugs treat sleep problems directly?
No. The authors said the analysis could not separate sleep improvement from relief of hot flashes and other vasomotor symptoms. Sleep was measured through patient-reported questionnaires.
Did one drug perform better than the other?
Subgroup analyses estimated larger effects for elinzanetant than fezolinetant at four and 12 weeks. However, the researchers said direct head-to-head trials are needed; the results do not establish which drug is better for an individual patient.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
